Literature DB >> 1613113

Parents' knowledge of neonatal screening and response to false-positive cystic fibrosis testing.

A Tluczek1, E H Mischler, P M Farrell, N Fost, N M Peterson, P Carey, W T Bruns, C McCarthy.   

Abstract

Neonatal screening for cystic fibrosis (CF) has become feasible through analyzing dried blood specimens for immunoreactive trypsinogen (IRT), but the benefits and risks of such a screening program remain to be delineated. This study, a survey of the parents of 104 Wisconsin infants with false-positive IRT tests, showed parents had knowledge deficits about neonatal screening in general, misconceptions about test results, and high levels of anxiety. Parenting behaviors were reportedly unchanged during the usual 3-day waiting period between the news of the abnormal screening test and the diagnostic sweat test. Most, but not all, parents were relieved by negative sweat test results subsequent to the abnormal IRT test. Factors associated with continued parental concern included having less than a high school education and/or having an infant with low Apgar scores. Additionally, those contacted by telephone were more likely to have misinformation and lingering concerns about the presence of CF in their child.

Entities:  

Mesh:

Year:  1992        PMID: 1613113

Source DB:  PubMed          Journal:  J Dev Behav Pediatr        ISSN: 0196-206X            Impact factor:   2.225


  28 in total

1.  Telephone use in primary care. Programme to shape demand has been started in several practices.

Authors:  John Oldham
Journal:  BMJ       Date:  2002-09-07

2.  Newborn Screening for Lysosomal Storage Disorders: Views of Genetic Healthcare Providers.

Authors:  Emily C Lisi; Shawn E McCandless
Journal:  J Genet Couns       Date:  2015-08-29       Impact factor: 2.537

3.  Quality improvement ethics: lessons from the SUPPORT study.

Authors:  Benjamin S Wilfond
Journal:  Am J Bioeth       Date:  2013       Impact factor: 11.229

4.  The effect of disruptions during counseling on recall of genetic risk information: the case of cystic fibrosis.

Authors:  James Price Dillard; Lijiang Shen; Audrey Tluczek; Peggy Modaff; Philip Farrell
Journal:  J Genet Couns       Date:  2007-04       Impact factor: 2.537

5.  Psychosocial Distress and Knowledge Deficiencies in Parents of Children in Ireland Who Carry an Altered Cystic Fibrosis Gene.

Authors:  S J Quigley; B Linnane; S Connellan; A Ward; P Ryan
Journal:  J Genet Couns       Date:  2017-09-26       Impact factor: 2.537

6.  Factors that influence parents' experiences with results disclosure after newborn screening identifies genetic carrier status for cystic fibrosis or sickle cell hemoglobinopathy.

Authors:  Jenelle L Collins; Alison La Pean; Faith O'Tool; Kerry L Eskra; Sara J Roedl; Audrey Tluczek; Michael H Farrell
Journal:  Patient Educ Couns       Date:  2012-01-11

7.  Primary care providers' role in newborn screening result notification for cystic fibrosis.

Authors:  Robin Z Hayeems; Fiona A Miller; Carolyn J Barg; Yvonne Bombard; Pranesh Chakraborty; Beth K Potter; Sarah Patton; Jessica Peace Bytautas; Karen Tam; Louise Taylor; Elizabeth Kerr; Christine Davies; Jennifer Milburn; Felix Ratjen; Astrid Guttmann; June C Carroll
Journal:  Can Fam Physician       Date:  2021-06       Impact factor: 3.275

8.  A comparative cost analysis of newborn screening for classic congenital adrenal hyperplasia in Texas.

Authors:  C A Brosnan; P Brosnan; B L Therrell; C H Slater; J M Swint; J F Annegers; W J Riley
Journal:  Public Health Rep       Date:  1998 Mar-Apr       Impact factor: 2.792

9.  Application of DNA analysis in a population-screening program for neonatal diagnosis of cystic fibrosis (CF): comparison of screening protocols.

Authors:  R G Gregg; B S Wilfond; P M Farrell; A Laxova; D Hassemer; E H Mischler
Journal:  Am J Hum Genet       Date:  1993-03       Impact factor: 11.025

10.  Neonatal screening for cystic fibrosis: France rises to the challenge.

Authors:  J P Farriaux; M Vidailhet; M L Briard; V Belot; J L Dhondt
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.